The role of the renin-angiotensin system gene polymorphisms in the development of carbohydrate disorders in patients with arterial hypertension-Reference-Cited by-同舟云学术

The role of the renin-angiotensin system gene polymorphisms in the development of carbohydrate disorders in patients with arterial hypertension

Published:2019-11-04 Issue:3 Volume:34 Page:33-39
ISSN:2073-8552
Container-title:The Siberian Medical Journal
language:
Short-container-title:SMJ

Author:

Zhuravlyova L. V.¹^ORCID,Kulikova M. V.¹^ORCID

Affiliation:

1. Kharkiv National Medical University

Abstract

Arterial hypertension and type 2 diabetes mellitus are the most widespread comorbid pathologies. The coexistence of these disorders accelerates the development of micro- and macrovascular complications, considerably increases the cardiovascular risk, as well as the risk of stroke and end stage renal disease. The synergism of these two pathologies is caused by the unity of pathogenetic mechanisms. Genetic predisposition also contributes to the development of both pathologies. It is well known that blockade of the renin-angiotensin system slows down the development of type 2 diabetes mellitus and also reduces the frequency of cardiovascular or kidney events in patients with these disorders. Gene polymorphisms of the reninangiotensin system are thoughtfully studied in the context of cardiovascular disease development. Currently, the role of gene polymorphisms in the development of carbohydrate disorders is not established, however, there is a high probability of their influence and importance. The purpose of review is to analyze the accumulated data on the effects of the renin-angiotensin system gene polymorphisms on the development of arterial hypertension and type 2 diabetes mellitus.

Publisher

Cardiology Research Institute

Reference44 articles.

1. Medical-demographic situation and key indicators of medical care to the population in regional aspect: 2012. Kiev: PI “Ukrainian Institute of Strategic Researches of the Ministry of Health of Ukraine”; 2013:190 (In Ukr.).

2. Netyazhenko V.Z., Ambrosova T.N., Gidzinskaya I.N., Kovalyova O.N., Melina I.N., Sirenko Yu.N. et al. Arterial hypertension. The updated and adapted clinical protocol based on proofs (2012). Working group on arterial hypertension of the Ukrainian association of cardiologists. Arterial Hypertension. 2012;1(21):96–152 (In Ukr.).

3. De Boer I.H., Bangalore S., Benetos A., Davis A.M., Michos E.D., Muntner P. et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–1284. DOI: 10.2337/dci17-0026.

4. Mamedov M.N., Gorbunova N.V., Kisеleva N.V., Oganov R.G. Features of structurally functional changes of a myocardium and haemo dynamic violations at patients with a metabolic syndrome: contribution of an arterial hypertension to formation of total coronary risk. Kardiologiia. 2005;45(11):11–16. (In Russ.).

5. Leoncini G., Ratto E., Viazzi F., Vaccaro V., Parodi D., Parodi A. et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J. Intern. Med. 2005;257: 454–460.